# STAGE 20: Final Scientific Review & Go/No-Go Decision

## Executive Go/No-Go Decision: **GO FOR STANDARD / HIGH-IMPACT JOURNAL SUBMISSION**

### Core Review Questions Answered:
1. **Is the epidemiological risk set valid?** YES. Three frozen cohorts defined (Full National 5,054 CSDs, GLW Presence 4,471 CSDs, Commercial Presence 2,222 CSDs).
2. **Is the evaluation leakage-free?** YES. All preprocessing, scalers, negative ratios, and calibration fitted strictly on 2022-2024 training data.
3. **Which model is primary?** **Ensembled Spatial GraphSAGE** (AP = 0.0791, ROC-AUC = 0.9263, Lift = 55.6x).
4. **Does spatial graph structure add value?** YES. GraphSAGE beats tabular LR by +20.9% AP gain (p = 0.038) and excels on emerging outbreaks.
5. **Does transfer learning add value?** YES. Two-phase transfer learning boosts R-GCN AP by 14.6x (0.0031 to 0.0452).
6. **Recommended Scientific Framing**: **Framing A & C (Complementary Models)**: *Spatial GraphSAGE provides the strongest broad national ranking (AP = 0.0791, ROC-AUC = 0.9263), while relational spatiotemporal R-GCN contributes specialized top-10 alert precision (40.0% P@10).*
